Role of FDG-PET in Evaluation of Myocardial Viability.
In many patients with chronic coronary artery disease, impaired left ventricular function at rest arises in part from regions of ischemic or hibernating myocardium rather than scarred myocardium. Evaluation of myocardial viability in heart failure allows for the prospective identification of patients with potentially reversible left ventricular dysfunction in whom prognosis may be favorably altered with coronary artery revascularization. This article reviews the role of F18-fluorodexyglucose PET myocardial viability testing in the management of patients with chronic left ventricular dysfunction and in guiding therapeutic decisions for revascularization.